Adverse effects of hydroxyurea in β-thalassemia intermedia patients: 10 years’ experience

Pediatric Hematology and Oncology

Volumn 27, Issue 3, 2010, Pages 205-211

  Karimi, Mehran ^a   Cohan, Nader ^a   Moosavizadeh, Kazem ^b   Falahi, Mohammad Javad ^b   Haghpanah, Sezaneh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse effects; Hydroxyurea; Thalassemia intermedia

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGE; ALOPECIA; ANOREXIA; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG TOLERABILITY; FACE ERYTHEMA; FECES COLOR; FEMALE; HEADACHE; HUMAN; HYPERPIGMENTATION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PARTIAL ALOPECIA; SIDE EFFECT; SPLENECTOMY; THALASSEMIA INTERMEDIA; TREATMENT DURATION; BETA THALASSEMIA; PRESCHOOL CHILD;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYUREA; MALE;

EID: 77953919319     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880011003639952     Document Type: Article

References (23)

1. Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusiondependent β-thalassemia patients. Haematologica. 2004;89:1172-1178.
2. Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol. 2001;40:530-534.
3. Biron F, Ponceeau B, Bouhour D, et al. Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients. J Acquir Immune Defic Syndr. 2000;25:329-336.
4. Karimi M, Borzouee M, Mehrabani A,Cohan N. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. Eur J Haematol. 2009;82:213-218.
5. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138:291-304.
6. Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci. 1998;850:120-128.
7. Hajjar FM, Pearson H. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125:490-492.
8. Zeng YT, Huang SZ, Ren ZR, et al. Hydroxyurea therapy in β-thalassemia intermedia: improvement in hematological parameters due to enhanced β-globin synthesis. Br J Hematol. 1995;90:557-563.
9. Karimi M, Darzi H, Yavarian M. Hematological and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27:380-385.
10. Arruda VR, Lima CS, Saad ST, Costa FF. Successful use of hydroxyurea in beta-thalassemia major. N Engl J Med. 1997;336(13):964.
11. Bradei M, Tayeb Abad M, et al. Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood. 2003;102:1529-1530.
12. Saxon BR, Waye JS, Olivier NF. Increase in hemoglobin concentration during therapy with hydroxyurea in Cooley’s anemia. Ann N Y Acad Sci. 1998;850:459-460.
13. Erlandson ME, Brilliant R, Smith CH. Comparison of sixty-six patients with thalassemia major and thirteen patients with thalassemia intermedia: including evaluations of growth, development, maturation and prognosis. Ann N Y Acad Sci. 1964;119:727-735.
14. Savona-Ventura C, Bonello F. Beta-thalassemia syndromes and pregnancy. Obstet Gynecol Surv. 1994;49(2):129-137.
15. Pearson Ha. Thalassemia intermedia; genetic and biochemical considerations. Ann N Y Acad Sci. 1964;119:390-401.
16. Tefferi A, Elliot MA, Kao PC, et al. Hydroxyurea-induced marked oscillation of platelet counts in patients with polycythemia vera. Blood. 2000;96:1582-1584.
17. Bénédicte C, Neonate MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol. 2001;137:467-470.
18. Zargari O, Kimyai-Asadi A, Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermedia thalassemia. Pediatr Dermatol. 2004;21:633-635.
19. De Montalembert M, Begue P, Bernaudin F, et al. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child. 1999;81:437-439.
20. Najean Y, Rain JD, for the French Polycythemia Study Group. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377.
21. Tothova E, Nebesnakova E, Kafkova A, et al. Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities. Vnitr Lek. 1999;45:487-489.
22. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential treated with hydroxyurea: high proportion of cases with 17p deletions. Blood. 1998;91:616-622.
23. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577-583.